The worldwide drug device combination products market was projected to be worth about USD 65 billion in 2012. It is predicted to increase over the forecast phase, at about 8 percent CAGR. The market is predicted to touch USD 115 billion by the end of the phase.
The drug device combination products market is driven principally by growing cases of cardiovascular illnesses and painful abnormalities. Diabetes, asthma, obesity, some other chronic illnesses and a fast emerging population of old people also drive the market.
The drug device combination products market is segmented into two categories. These include different kinds and geographical regions.